Summary
Accumulating evidence suggests that a disruption of early brain development, in which insulin-like growth factor-2 (IGF-2) has a crucial role, may underlie the pathophysiology of schizophrenia. Our previous study has shown that decreased serum IGF-2 was correlated with the severity of psychopathology in patients with schizophrenia. Here we conducted a prospective observation trial to investigate the effects of atypical antipsychotics on serum IGF-2 level and its relationship with clinical improvements in schizophrenia patients. Thirty-one schizophrenia patients with acute exacerbation and 30 healthy individuals were recruited in this study. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and serum IGF-2 levels were determined using ELISA. We found that schizophrenia patients with acute exacerbation had lower serum IGF-2 levels than control individuals at baseline (P<0.05). After 2 months of atypical antipsychotic treatment, a significant improvement in each PANSS subscore and total score was observed in patients (all P<0.01), and the serum IGF-2 levels of patients were significantly increased compared with those at baseline (203.13±64.62 vs. 426.99±124.26 ng/mL; t =−5.044, P<0.001). Correlation analysis revealed that the changes of serum IGF-2 levels in patients were significantly correlated with the improvements of negative symptoms (r=−0.522, P=0.006). Collectively, our findings demonstrated changes of serum IGF-2 response to improvements of negative symptoms in schizophrenia patients treated with atypical antipsychotics, suggesting that serum IGF-2 might be a treatment biomarker for schizophrenia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Change history
29 October 2020
The article “Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics”, written by Xue-lin CHAO, Shu-zhen JIANG, Jian-wen XIONG, Jin-qiong ZHAN, Bo WEI, Chun-nuan CHEN, Yuan-jian YANG was originally published electronically on the publisher’s internet portal on June 2020 without open access. With the author(s)’ decision to opt for Open Choice, the copyright of the article is changed to — The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
23 February 2021
An Erratum to this paper has been published: https://doi.org/10.1007/s11596-020-2256-3
References
Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet, 2016, 388(10039):86–97
Mueser KT, McGurk SR. Schizophrenia. Lancet, 2004, 363(9426):2063–2072
Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull, 2015, 114(1):169–179
Sanchez JPB, Ellenbroek BA. Preclinical Effects of Antipsychotic Drugs. Curr Top Behav Neurosci,2017, 34:1–16
Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med, 2001, 52:503–517
Muller-Spahn F. Current use of atypical antipsychotics. Eur Psychiatry, 2002, 17 Suppl 4:377s–384s
Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag, 2017, 13:757–777
Gallhofer B, Bauer U, Lis S, et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol, 1996,6 Suppl 2:S13–20
Krakowski MI, Czobor P, Nolan KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol, 2008, 28(5):485–493
van Os J, Kapur S. Schizophrenia. Lancet, 2009,374(9690):635–645
Zhao C, Zhu J, Liu X, et al. Structural and functional brain abnormalities in schizophrenia: A cross-sectional study at different stages of the disease. Prog Neuropsy-chopharmacol Biol Psychiatry, 2018, 83:27–32
Cannon M, Caspi A, Moffitt TE, et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry, 2002,59(5):449–456
Benarroch EE. Insulin-like growth factors in the brain and their potential clinical implications. Neurology, 2012, 79(21):2148–2153
O’Kusky J, Ye P. Neurodevelopmental effects of insulinlike growth factor signaling. Front Neuroendocrinol, 2012, 33(3):230–251
Fromer M, Roussos P, Sieberts SK, et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci, 2016, 19(11):1442–1453
Pai S, Li P, Killinger B, et al. Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis. Nat Commun, 2019, 10(1):2046
Akanji AO, Ohaeri JU, Al-Shammri SA, et al. Associations of blood levels of insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-3 in schizophrenic Arab subjects. Clin Chem Lab Med, 2007, 45(9):1229–1231
Yang YJ, Luo T, Zhao Y, et al. Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia. PLoS One, 2020, 15(3):e0226688
Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry, 2004, 161(2 Suppl):1–56
Mortimer AM. Antipsychotic treatment in schizophrenia: atypical options and NICE guidance. Eur Psychiatry, 2003, 18(5):209–219
Peralta V, de Leon J, Cuesta MJ. Are there more than two syndromes in schizophrenia? A critique of the positivenegative dichotomy. Br J Psychiatry, 1992, 161:335–343
Dollfus S, Lyne J. Negative symptoms: History of the concept and their position in diagnosis of schizophrenia. Schizophr Res, 2017, 186:3–7
Palmer BW, Dawes SE, Heaton RK. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol Rev, 2009, 19(3):365–384
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 2013, 382(9896):951–962
Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA, 2011, 306(12):1359–1369
Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol, 2005, 8(3):457–472
Fernandez AM, Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci, 2012, 13(4):225–239
Russo VC, Gluckman PD, Feldman EL, et al. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev, 2005, 26(7):916–943
Logan A, Gonzalez AM, Hill DJ, et al. Coordinated pattern of expression and localization of insulin-like growth factor-II (IGF-II) and IGF-binding protein-2 in the adult rat brain. Endocrinology, 1994, 135(5):2255–2264
Shamblott MJ, Leung S, Greene MW, et al. Characterization of a teleost insulin-like growth factor II (IGF-II) gene: evidence for promoter CCAAT/enhancer-binding protein (C/EBP) sites, and the presence of hepatic C/EBP. Mol Mar Biol Biotechnol, 1998, 7(3):181–190
Chen DY, Stern SA, Garcia-Osta A, et al. A critical role for IGF-II in memory consolidation and enhancement. Nature, 2011, 469(7331):491–497
Chase KA, Rosen C, Gin H, et al. Metabolic and inflammatory genes in schizophrenia. Psychiatry Res, 2015, 225(1–2):208–211
Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain, 1999,122(Pt 4):593–624
Han QQ, Shen TT, Wang F, et al. Preventive and Therapeutic Potential of Vitamin C in Mental Disorders. Curr Med Sci, 2018, 38(1):1–10
Shukla DK, Chiappelli JJ, Sampath H, et al. Aberrant Frontostriatal Connectivity in Negative Symptoms of Schizophrenia. Schizophr Bull, 2019, 45(5):1051–1059
Brady RO, Jr., Gonsalvez I, Lee I, et al. Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia. Am J Psychiatry, 2019, 176(7):512–520
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.
Additional information
This work was supported by grants from the National Natural Science Foundation of China (No. 81760254), the Natural Science Foundation of Fujian Province of China (No. 2019J01164) and the Scientific Foundation of Quanzhou City for High Level Talents (No. 2019C075R).
The original online version of this article was revised. The
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chao, Xl., Jiang, Sz., Xiong, Jw. et al. Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics. CURR MED SCI 40, 563–569 (2020). https://doi.org/10.1007/s11596-020-2214-0
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-020-2214-0